-
May 16, 2013
Novo Nordisk's chief executive Lars Rebien Sorensen has accused politicians in some European countries of making empty promises to their populations in terms of access to innovative drugs and called for more harmonisation of regulatory systems across the globe
Full story
-
May 01, 2013
Novo Nordisk has posted yet another stellar set of figures, helped by strong sales of its diabetes drug Victoza
Full story
-
April 09, 2013
Patients with advanced skin cancer living in Scotland will be given National Health Service access to the first new medicine for the disease to be licensed in the UK in more than 30 years.
Full story
-
March 05, 2013
Patients with diabetes in the UK can now get access to a new treatment option following the roll out of Novo Nordisk's ultra-long-acting insulin Tresiba in the country, marking its first launch in Europe.
Full story
-
February 12, 2013
Novo Nordisk has suffered a huge blow after US regulators refused to approve its new insulin Tresiba.
Full story
-
January 22, 2013
Novo Nordisk is celebrating after European regulators gave the green light to Tresiba and Ryzodeg, which the Danish company hopes will challenge Sanofi's Lantus, the world's biggest-selling insulin product
Full story
-
November 09, 2012
Shares in Novo Nordisk have soared this morning after an FDA panel recommended approval of Tresiba and Ryzodeq, despite expressing concerns over possible cardiovascular risk of the ultra long-acting insulins
Full story
-
November 07, 2012
Shares in Danish drugmaker Novo Nordisk slipped after it emerged that US health officials remain concerned over the heart safety of its diabetes drug Tresiba
Full story
-
November 01, 2012
Novo Nordisk has posted another healthy set of figures for the third quarter, helped by strong sales of diabetes drug Victoza and its modern insulins
Full story
-
October 22, 2012
Recommendations from EMA advisors include rejecting Lundbeck’s Acrescent for Alzheimer’s disease, and approving Novo Nordisk's diabetes drugs Tresiba and Ryzodeg.
Full story